Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2017

View Archived Issues

Threshold Pharmaceuticals and Molecular Templates agree to merge

NightstaRx initiates phase I/II study of gene therapy to treat X-linked retinitis pigmentosa

EURE-CART project holds launch meeting

Opiant initiates phase II trial of OPNT-001 for bulimia nervosa

BioLineRx reports partial results from phase II trial of BL-8040 for mobilization of stem cells

Actelion Pharmaceuticals presents novel antibacterial compounds

Lupin discovers new sodium channel protein type 9 subunit alpha blockers

OncoArendi Therapeutics patents chitinase and chitotriosidase-1 inhibitors

FORMA Therapeutics synthesizes new histone deacetylase 8 inhibitors

Nimbus Lakshmi presents novel TYK2 inhibitors

Tyrosine-protein kinase Mer inhibitors discovered at Dong-A Socio Holdings

Phase III MONARCH 2 breast cancer study of abemaciclib meets primary endpoint

Jazz announces promising phase III results for JZP-110 in obstructive sleep apnea

Mallinckrodt closes sale of intrathecal therapy business to Piramal Critical Care

argenx collaborates with Broteio to develop therapeutic antibody for severe autoimmune diseases

Aevi reports topline results from SAGA trial of AEVI-001 in ADHD

Bristol-Myers Squibb and CytomX expand Probody discovery collaboration

FDA sets action date to complete NDA review for latanoprostene bunod

Global Genomics announces knowPLAQUE diagnostic blood test for plaque in coronary arteries

Loxo and Ventana Medical Systems collaborate on companion diagnostic for LOXO-101

First-in-human data presented for tenofovir disoproxil orotate

Full results reported for ORION-1 trial of inclisiran in patients at cardiovascular risk

Ra Pharmaceuticals initiates phase II study of RA-101495 for PNH

Ono Pharmaceutical and X-Chem form oncology discovery collaboration

Phase II data presented for buparlisib in patients with metastatic head and neck carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...